Emergent BioSolutions Inc. EBS

EBS Company Overview

Emergent BioSolutions Inc. is a U.S.-based biotechnology and life sciences company focused on products and services that address public health threats, infectious diseases, and preparedness needs for governments and healthcare systems. The company operates primarily in the biodefense, medical countermeasures, and specialty biopharmaceutical sectors, with activities spanning vaccine development, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent has historically generated a substantial portion of its revenue through sales to the U.S. government and allied public-sector customers, particularly through procurement contracts tied to national stockpile and preparedness programs.

The company’s core business lines include marketed medical countermeasures such as anthrax vaccines, opioid overdose reversal products, and smallpox-related preparedness products, alongside contract manufacturing and development services through its CDMO operations. Key customer segments include U.S. federal agencies, international governments, healthcare providers, and pharmaceutical companies. Emergent traces its origins to BioPort Corporation, which acquired rights associated with the anthrax vaccine business in the late 1990s before evolving into Emergent BioSolutions through acquisitions, product diversification, and expansion into biodefense and public health response capabilities. The company’s strategic positioning has historically been tied to specialized manufacturing capacity, long-term government relationships, and expertise in regulated biologics production.